Johnson & Johnson’s Injectable Rybrevant Shows Promise in Extending Lives of Lung Cancer Patients
Johnson & Johnson’s injectable Rybrevant has shown promising results in extending the lives of lung cancer patients, with a 38% reduction in the risk of death compared to the intravenous version. The subcutaneous formulation demonstrated better overall survival, longer duration of response, and lower infusion-related reactions. With plans to file for FDA approval, J&J aims to gain a competitive edge in the market against AstraZeneca’s Tagrisso.
Johnson & Johnson Reports Strong Fourth-Quarter Performance Despite Stock Drop
Johnson & Johnson (NYSE:JNJ) experienced a slight drop in its stock value despite reporting a strong fourth-quarter performance. The global healthcare giant saw a 7.3% year-over-year increase in revenue, reaching $21.4 billion, surpassing estimates by $380 million. Additionally, its earnings…